PubMed=36835416; DOI=10.3390/ijms24044007; PMCID=PMC9965047
Ryo Ejima, Hiroyuki Suzuki, Tomohiro Tanaka, Teizo Asano, Mika Kato Kaneko, Yukinari Kato;
Development of a novel anti-CD44 variant 6 monoclonal antibody C44Mab-9 for multiple applications against colorectal carcinomas.
Int. J. Mol. Sci. 24:4007.1-4007.16(2023)

PubMed=36975491; DOI=10.3390/cimb45030121; PMCID=PMC10047040
Hiroyuki Suzuki, Tomohiro Tanaka, Nohara Goto, Mika Kato Kaneko, Yukinari Kato;
Development of a novel anti-CD44 variant 4 monoclonal antibody C44Mab-108 for immunohistochemistry.
Curr. Issues Mol. Biol. 45:1875-1888(2023)

PubMed=37176118; DOI=10.3390/ijms24098411; PMCID=PMC10179237
Hiroyuki Suzuki, Kaishi Kitamura, Nohara Goto, Kenichiro Ishikawa, Tsunenori Ouchida, Tomohiro Tanaka, Mika Kato Kaneko, Yukinari Kato;
A novel anti-CD44 variant 3 monoclonal antibody C44Mab-6 was established for multiple applications.
Int. J. Mol. Sci. 24:8411.1-8411.17(2023)

PubMed=37185762; DOI=10.3390/cimb45040238; PMCID=PMC10137259
Mayuki Tawara, Hiroyuki Suzuki, Nohara Goto, Tomohiro Tanaka, Mika Kato Kaneko, Yukinari Kato;
A novel anti-CD44 variant 9 monoclonal antibody C44Mab-1 Was developed for immunohistochemical analyses against colorectal cancers.
Curr. Issues Mol. Biol. 45:3658-3673(2023)

PubMed=37189717; DOI=10.3390/biomedicines11041099; PMCID=PMC10136282
Hiroyuki Suzuki, Keiya Ozawa, Tomohiro Tanaka, Mika Kato Kaneko, Yukinari Kato;
Development of a novel anti-CD44 variant 7/8 monoclonal antibody, C44Mab-34, for multiple applications against oral carcinomas.
Biomedicines 11:1099.1-1099.15(2023)

PubMed=37218897; DOI=10.3390/antib12020031; PMCID=PMC10204397
Yuma Kudo, Hiroyuki Suzuki, Tomohiro Tanaka, Mika Kato Kaneko, Yukinari Kato;
Development of a novel anti-CD44 variant 5 monoclonal antibody C44Mab-3 for multiple applications against pancreatic carcinomas.
Antibodies (Basel) 12:31.1-31.16(2023)

PubMed=37489367; DOI=10.3390/antib12030045; PMCID=PMC10366929
Hiroyuki Suzuki, Nohara Goto, Tomohiro Tanaka, Tsunenori Ouchida, Mika Kato Kaneko, Yukinari Kato;
Development of a novel anti-CD44 variant 8 monoclonal antibody C44Mab-94 against gastric carcinomas.
Antibodies (Basel) 12:45.1-45.17(2023)

PubMed=37504249; DOI=10.3390/cimb45070333; PMCID=PMC10378409
Kenichiro Ishikawa, Hiroyuki Suzuki, Mika Kato Kaneko, Yukinari Kato;
Establishment of a novel anti-CD44 variant 10 monoclonal antibody C44Mab-18 for immunohistochemical analysis against oral squamous cell carcinomas.
Curr. Issues Mol. Biol. 45:5248-5262(2023)